Follow RSS for latest reports on this topicErtugliflozin - Market Research and Reports
Ertugliflozin a sodium glucose cotransporter-2 (SGLT2) inhibitor, under development by Pfizer and Merck & Co. for the treatment of type 2 diabetes (T2D). By blocking SGLT2 in the proximal tubules of the kidney, ertugliflozin removes excess glucose in the blood by preventing the reabsorption of filtered glucose.
BioPortfolio's Easy Ordering System
- Search for the report you need from our store
- Make online payment with our easy checkout process
- Receive PDF report via email
Easy Online Payment or Pro Forma Invoice
We accept the following credit cards...
or can supply a pro-forma invoice if required.